The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer
Abstract
Purpose: To determine the safety and efficacy of weekly high-dose oral calcitriol (Rocaltrol, Roche Pharmaceuticals, Basel, Switzerland) and docetaxel (Taxotere, Aventis Pharmaceuticals, Bridgewater, NJ) in patients with metastatic androgen-independent prostate cancer (AIPC). Patients and Methods: Thirty-seven patients were treated with oral calcitriol (0.5 μg/kg) on day 1 followed by docetaxel (36 mg/m 2) on day 2, repeated weekly for 6 weeks of an 8-week cycle. Patients maintained a reduced calcium diet and increased oral hydration. Prostate-specific antigen (PSA) response was the primary end point, which was defined as a 50% reduction in PSA level confirmed 4 weeks later. Results: Thirty of 37 patients (81%; 95% confidence interval [CI], 68% to 94%) achieved a PSA response. Twenty-two patients (59%; 95% CI, 43% to 75%) had a confirmed > 75% reduction in PSA. Eight of the 15 patients with measurable disease (53%; 95% CI, 27% to 79%) had a confirmed partial response. Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable). Overall survival at 1 year was 89% (95% CI, 74% to 95%). Treatment-related toxicity was generally similar to that expected with single-agent docetaxel. Pharmacokinetics of either calcitriol or docetaxel were not affected by the presence of its companion drug in an exploratory substudy. Conclusion: The combination of weekly oral high-dose calcitriol and weekly docetaxel is a well-tolerated regimen for AIPC. PSA and measurable disease response rates as well as time to progression and survival are promising when compared with contemporary phase II studies of single-agent docetaxel in AIPC. Further study of this regimen is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3.
Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Yoshiki, S., & Suda, T. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.8.4990 · Cited by 1,020
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Liu, M., Lee, M. H., Cohen, M., Bommakanti, M., & Freedman, L. P. (1996) · Genes & Development · doi:10.1101/gad.10.2.142 · Cited by 890
Translational Control of p27 Kip1 Accumulation During the Cell Cycle
Hengst, L., & Reed, S. I. (1996) · Science · doi:10.1126/science.271.5257.1861 · Cited by 846
COLSTON, K., COLSTON, M. J., & FELDMAN, D. (1981) · Endocrinology · doi:10.1210/endo-108-3-1083 · Cited by 558
Skowroński, R., Peehl, D. M., & Feldman, D. I. (1993) · Endocrinology · doi:10.1210/en.132.5.1952 · Cited by 494
Cited by
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Nutrition and physical activity guidelines for cancer survivors
Rock, C. L., Doyle, C., Demark‐Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., Bandera, E. V., Hamilton, K. K., Grant, B., McCullough, M., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21142 · Cited by 1,995
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
Noncalcemic Actions of Vitamin D Receptor Ligands
Nagpal, S., Na, S., & Rathnachalam, R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0002 · Cited by 961
Doyle, C., Kushi, L. H., Byers, T., Courneya, K. S., Demark-Wahnefried, W., Grant, B., McTiernan, A., Rock, C. L., Thompson, C., Gansler, T., et al. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.6.323 · Cited by 950
Metadata
- Authors
- Beer, T. M., Eilers, K. M., Garzotto, M., Egorin, M. J., Lowe, B. A., & Henner, W. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-01-01
- Volume
- 21
- Issue
- 1
- Pages
- 123-128
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2064536538
- Cited by
- 253
- References
- 33
- FWCI
- 21.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2003.05.117
- The paper
- Beer, T. M., Eilers, K. M., Garzotto, M., Egorin, M. J., Lowe, B. A., & Henner, W. D. (2003). Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.05.117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.